The stock price of TMDX has experienced a decrease from October 29 to November 11. The decline in TransMedics Group's (TMDX) stock price can be attributed to the following factors:
- Q3 Earnings Disappointment: TransMedics Group reported disappointing third-quarter 2024 results, with revenue of $108.8 million and net income of $4.2 million, both below analysts' estimates. This news led to a significant drop of nearly 30% in the company's stock price2.
- Investor Concerns: There are concerns about the company's performance, such as industry volumes during the traditional weaker period, maintenance of several planes, and a recent slowdown in U.S. organ transplant volumes. These factors contributed to investors' worries, leading to a decrease in the stock price3.
In summary, the decline in TMDX's stock price is primarily due to Q3 earnings disappointment and investor concerns.